Patents by Inventor Marcia Belvin

Marcia Belvin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
    Publication number: 20180280408
    Abstract: Methods and compositions are provided for treating hyperproliferative disorders in patients with a PI3K inhibitor, GDC-0032 as a single agent or in combination with chemotherapeutic agents.
    Type: Application
    Filed: February 14, 2018
    Publication date: October 4, 2018
    Applicant: Genentech, Inc.
    Inventors: Marcia Belvin, Lori Friedman, Deepak Sampath, Jeffrey Wallin
  • Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
    Patent number: 9532987
    Abstract: The invention provides combinations comprising a MEK inhibitor (such as GDC-0973 or GDC-0623), or a pharmaceutically acceptable salt thereof and an ERK inhibitor (such as GDC-0994). The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: January 3, 2017
    Assignee: Genentech, Inc.
    Inventors: Marcia Belvin, John Moffat, Mark Merchant
  • MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
    Publication number: 20160045515
    Abstract: Methods and compositions are provided for treating hyperproliferative disorders in patients with a PI3K inhibitor, GDC-0032 as a single agent or in combination with chemotherapeutic agents.
    Type: Application
    Filed: July 6, 2015
    Publication date: February 18, 2016
    Applicant: Genentech, Inc.
    Inventors: Marcia Belvin, Lori Friedman, Deepak Sampath, Jeffrey Wallin
  • Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
    Patent number: 9107926
    Abstract: Methods and compositions are provided for treating hyperproliferative disorders in patients with a PI3K inhibitor, GDC-0032 as a single agent or in combination with chemotherapeutic agents.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: August 18, 2015
    Assignee: GENENTECH, INC.
    Inventors: Marcia Belvin, Lori Friedman, Deepak Sampath, Jeffrey Wallin
  • USE OF A COMBINATION OF A MEK INHIBITOR AND AN ERK INHIBITOR FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES
    Publication number: 20150111869
    Abstract: The invention provides combinations comprising a MEK inhibitor (such as GDC-0973 or GDC-0623), or a pharmaceutically acceptable salt thereof and an ERK inhibitor (such as GDC-0994). The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
    Type: Application
    Filed: August 29, 2014
    Publication date: April 23, 2015
    Applicant: Genentech, Inc.
    Inventors: Marcia Belvin, John Moffat, Mark Merchant
  • SCDs as modifiers of the p53 pathway and methods of use
    Patent number: 8771942
    Abstract: Human SCD genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SCD are provided.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: July 8, 2014
    Assignee: Exelixis, Inc.
    Inventors: Marcia Belvin, Helen Francis-Lang, Lori Friedman, Gregory D. Plowman, Timothy S. Heuer
  • MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
    Publication number: 20140044706
    Abstract: Methods and compositions are provided for treating hyperproliferative disorders in patients with a PI3K inhibitor, GDC-0032 as a single agent or in combination with chemotherapeutic agents.
    Type: Application
    Filed: June 7, 2013
    Publication date: February 13, 2014
    Inventors: Marcia Belvin, Lori Friedman, Deepak Sampath, Jeffrey Wallin
  • COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE
    Publication number: 20130345217
    Abstract: Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: August 28, 2013
    Publication date: December 26, 2013
    Applicant: Genentech, Inc.
    Inventors: Marcia Belvin, Lori Friedman, Klaus P. Hoeflich, Jeffrey Wallin
  • Combinations of phosphoinositide 3-kinase inhibitor compounds chemotherapeutic agents, and methods of use
    Patent number: 8604014
    Abstract: Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: December 10, 2013
    Assignees: Genentech, Inc., F. Hoffmann-La Roche AG
    Inventors: Marcia Belvin, Lori Friedman, Klaus Hoeflich, Deepak Sampath, Ulka Vijapurkar, Jeffrey Wallin, Leisa Johnson, Mallika Singh, Sonal Patel
  • MAP3Ks as modifiers of the p53 pathway and methods of use
    Patent number: 8268548
    Abstract: Human MAP3K genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MAP3K are provided.
    Type: Grant
    Filed: April 18, 2007
    Date of Patent: September 18, 2012
    Assignee: Exelixis, Inc.
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danix Li, Roel P. Funke
  • Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
    Patent number: 8247397
    Abstract: Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: August 21, 2012
    Assignees: Genentech, Inc., F. Hoffman-La Roche AG
    Inventors: Marcia Belvin, Lori Friedman, Klaus Hoeflich, Deepak Sampath, Ulka Vijapurkar, Jeffrey Wallin, Leisa Johnson, Mallika Singh, Sonal Patel
  • Marks as modifiers of the p53 pathway and methods of use
    Patent number: 8153384
    Abstract: Human MARK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MARK are provided.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: April 10, 2012
    Assignee: Exelixis, Inc.
    Inventors: Lori Friedman, Gregory D. Plowman, Helen Francis-Lang, Danxi Li, Roel P. Funke, Marcia Belvin, Mario N. Lioubin
  • COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE
    Publication number: 20110223619
    Abstract: Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: May 17, 2011
    Publication date: September 15, 2011
    Applicants: Genentech, Inc., F. Hoffmann-La Roche AG
    Inventors: Marcia Belvin, Lori Friedman, Klaus Hoeflich, Deepak Sampath, Ulka Vijapurkar, Jeffrey Wallin, Leisa Johnson, Mallika Singh, Sonal Patel
  • GFATS as Modifiers of the P53 Pathway and Methods of Use
    Publication number: 20110159508
    Abstract: Human GFAT genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of GFAT are provided.
    Type: Application
    Filed: October 7, 2010
    Publication date: June 30, 2011
    Applicant: EXELIXIS, INC.
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke
  • COMBINATIONS OF A PI3K INHIBITOR AND A MEK INHIBITOR
    Publication number: 20110086837
    Abstract: The invention relates methods of treating a patient with locally advanced or metastatic solid tumors with a combination of an inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase or PI3K) and an inhibitor of mitogen activated protein kinase (MEK) described herein.
    Type: Application
    Filed: October 11, 2010
    Publication date: April 14, 2011
    Applicant: Genentech, Inc.
    Inventors: Marcia Belvin, Iris T. Chan, Lori Friedman, Klaus P. Hoeflich, John Prescott, Jeffrey Wallin
  • Marks as modifiers of the p53 pathway and methods of use
    Publication number: 20100325743
    Abstract: Human MARK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MARK are provided.
    Type: Application
    Filed: June 10, 2010
    Publication date: December 23, 2010
    Applicant: Exelixis, Inc.
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke, Mario N. Lioubin
  • HADHs as Modifiers of the p21 Pathway and Methods of Use
    Publication number: 20100275275
    Abstract: Human HADH genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of HADH are provided.
    Type: Application
    Filed: August 5, 2009
    Publication date: October 28, 2010
    Applicant: EXELIXIS INC.
    Inventors: Lori Friedman, Gregory D. Plowman, Roel P. Funke, Marcia Belvin, Danxi Li, Stephanie A. Robertson
  • SCDs As Modifiers of the p53 Pathway and Methods of Use
    Publication number: 20100159470
    Abstract: Human SCD genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SCD are provided.
    Type: Application
    Filed: February 26, 2010
    Publication date: June 24, 2010
    Applicant: EXELIXIS, INC.
    Inventors: Marcia Belvin, Helen Francis-Lang, Lori Friedman, Gregory D. Plowman, Timothy S. Heuer
  • COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE
    Publication number: 20090098135
    Abstract: Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: September 10, 2008
    Publication date: April 16, 2009
    Inventors: Marcia Belvin, Lori Friedman, Klaus Hoeflich, Deepak Sampath, Ulka Vijapurkar, Jeffrey Wallin, Leisa Johnson, Mallika Singh, Sonal Patel
  • MAP3Ks as modifiers of the p53 pathway and methods of use
    Publication number: 20090068186
    Abstract: Human MAP3K genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MAP3K are provided.
    Type: Application
    Filed: April 18, 2007
    Publication date: March 12, 2009
    Applicant: Exelixis Inc.
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke